IN8bio released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of USD 0 and EPS of USD -16.2288

Brief Summary

IN8bio reported a third-quarter loss with an EPS of -16.2288 USD and revenue of 0 USD, highlighting a stark contrast to peers like Amber International Holding Limited, which achieved record revenues in the first quarter of 2025.

Impact of The News

Financial Performance Overview

• Reported Figures: IN8bio’s financial briefing for the first three quarters of 2024 reveals an EPS of -16.2288 USD and no revenue.

Comparison with Peers

• Amber International Holding Limited: In contrast, Amber International showed strong financial performance, achieving a record revenue of 14.90 million USD in Q1 2025, driven by its wealth management solutions .
• Marvell Technology: Similarly, Marvell reported revenues of 1.9 billion USD in Q1 2026, supported by growth in data center and AI business sectors .
• CoreWeave: CoreWeave also demonstrated growth, benefiting from major deals like a 119 billion USD agreement with OpenAI .

Impact Analysis

• Market Expectations: The lack of revenue and significant EPS loss suggests IN8bio’s performance falls short of market expectations, especially when compared to industry peers who maintain positive growth trajectories.
• Business Status: The absence of revenue indicates potential operational challenges or lack of product commercialization, which might affect investor confidence and future funding.

Future Business Development

• Operational Strategies: IN8bio may need to reassess its business model and explore revenue-generating opportunities to improve financial health.
• Investor Sentiment: The current financial state may lead to decreased investor interest unless strategic changes are implemented.